160 related articles for article (PubMed ID: 28706485)
21. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
[TBL] [Abstract][Full Text] [Related]
22. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
[TBL] [Abstract][Full Text] [Related]
23. Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).
Blum KA; Polley MY; Jung SH; Dockter TJ; Anderson S; Hsi ED; Wagner-Johnston N; Christian B; Atkins J; Cheson BD; Leonard JP; Bartlett NL
Cancer; 2019 Oct; 125(19):3378-3389. PubMed ID: 31174236
[TBL] [Abstract][Full Text] [Related]
24. [Clinical Features, Treatment and Prognostic Factors of 94 Patients with Follicular Lymphoma].
DU XY; Hu K; Zhao W; Yang P; Wan W; Jing HM; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):756-764. PubMed ID: 29950216
[TBL] [Abstract][Full Text] [Related]
25. First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis.
Pouyiourou M; Meyer A; Stroux A; Viardot A; La Rosée P; Maschmeyer G; Kämpfe D; Kahl C; Vucinic V; Monecke A; Hirt C; Weber T; Meissner J; Witzens-Harig M; Böttcher S; Schmalenberg H; Marks R; Prange-Krex G; Kroschinsky F; Hauf E; Keller U; Koch K; Klapper W; Herold M; Scholz CW;
Ann Hematol; 2020 Dec; 99(12):2821-2829. PubMed ID: 32734548
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma.
Younes A; Burke JM; Diefenbach C; Ferrari S; Khan C; Sharman JP; Tani M; Ujjani C; Vitolo U; Yuen S; Raval A; Shivhare M; Nielsen TG; Sellam G; Gilbertson M
Blood Adv; 2022 Oct; 6(20):5659-5667. PubMed ID: 35359000
[TBL] [Abstract][Full Text] [Related]
27. [Curative effect analysis of rituximab combined with intensive chemotherapy for follicular lymphoma patients with bone marrow involvement].
Xiong W; Yi S; Li H; Liu H; Li Z; Lü R; Liu W; Zou D; Qiu L
Zhonghua Yi Xue Za Zhi; 2015 Nov; 95(44):3593-7. PubMed ID: 26813371
[TBL] [Abstract][Full Text] [Related]
28. Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial.
Rai S; Inoue H; Hanamoto H; Matsuda M; Maeda Y; Wada Y; Haeno T; Watatani Y; Kumode T; Hirase C; Espinoza JL; Morita Y; Tanaka H; Tatsumi Y; Matsumura I
Int J Hematol; 2021 Aug; 114(2):205-216. PubMed ID: 33864623
[TBL] [Abstract][Full Text] [Related]
29. Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin's Lymphoma and Role of
Zhang Y; He D; He J; Huang W; Yang Y; Cai Z; Zhao Y
Comput Math Methods Med; 2022; 2022():1080879. PubMed ID: 35096126
[TBL] [Abstract][Full Text] [Related]
30. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
[TBL] [Abstract][Full Text] [Related]
31. Bendamustine Plus Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Low-grade B-cell Lymphoma and Mantle Cell Lymphoma: A Single-Center Retrospective Study.
Murakami H; Yoshioka T; Moriyama T; Ishikawa T; Makita M; Sunami K
Acta Med Okayama; 2021 Aug; 75(4):461-469. PubMed ID: 34511613
[TBL] [Abstract][Full Text] [Related]
32. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
Mondello P; Steiner N; Willenbacher W; Wasle I; Zaja F; Zambello R; Visentin A; Mauro E; Ferrero S; Ghione P; Pitini V; Cuzzocrea S; Mian M
Ann Hematol; 2016 Jun; 95(7):1107-14. PubMed ID: 27103007
[TBL] [Abstract][Full Text] [Related]
33. Treatment Patterns and Survival Outcomes in Patients With Follicular Lymphoma: A 2007 to 2015 Humedica Database Study.
Morrison VA; Shou Y; Bell JA; Hamilton L; Ogbonnaya A; Raju A; Hennenfent K; Eaddy M; Galaznik A
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):e172-e183. PubMed ID: 30691994
[TBL] [Abstract][Full Text] [Related]
34. Consolidation with
Miura K; Tsujimura H; Masaki Y; Iino M; Takizawa J; Maeda Y; Yamamoto K; Tamura S; Yoshida A; Yagi H; Yoshida I; Kitazume K; Masunari T; Choi I; Kakinoki Y; Suzuki R; Yoshino T; Nakamura S; Hatta Y; Yoshida T; Kanno M
Hematol Oncol; 2021 Feb; 39(1):51-59. PubMed ID: 32978820
[TBL] [Abstract][Full Text] [Related]
35. Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL.
Tisi MC; Moia R; Patti C; Evangelista A; Ferrero S; Spina M; Tani M; Botto B; Celli M; Puccini B; Cencini E; Di Rocco A; Chini C; Ghiggi C; Zambello R; Zanni M; Sciarra R; Bruna R; Ferrante M; Pileri SA; Quaglia FM; Stelitano C; Re A; Volpetti S; Zilioli VR; Arcari A; Merli F; Visco C
Blood Adv; 2023 Aug; 7(15):3916-3924. PubMed ID: 37171620
[TBL] [Abstract][Full Text] [Related]
36. Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.
Genuardi E; Klous P; Mantoan B; Drandi D; Ferrante M; Cavallo F; Alessandria B; Dogliotti I; Grimaldi D; Ragaini S; Clerico M; Lo Schirico M; Saraci E; Yilmaz M; Zaccaria GM; Cortelazzo S; Vitolo U; Luminari S; Federico M; Boccadoro M; van Min M; Splinter E; Ladetto M; Ferrero S
Hematol Oncol; 2021 Aug; 39(3):293-303. PubMed ID: 33742718
[TBL] [Abstract][Full Text] [Related]
37. Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi.
Margiotta-Casaluci G; Bigliardi S; Cocito F; Meli E; Petrucci L; Nicolosi M; Annibali O; Boccomini C; Bozzoli V; Castellino A; Cattina F; Cenfra N; Ciavarella S; Kovalchuk S; Rotondo F; Fama A; Olivieri J; Zaja F
Front Oncol; 2023; 13():1120967. PubMed ID: 36969038
[TBL] [Abstract][Full Text] [Related]
38. Economic evaluation of sequential treatments for follicular non-hodgkin lymphoma.
Soini EJ; Martikainen JA; Vihervaara V; Mustonen K; Nousiainen T
Clin Ther; 2012 Apr; 34(4):915-925.e2. PubMed ID: 22459623
[TBL] [Abstract][Full Text] [Related]
39. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy.
Rodríguez-Sevilla JJ; Fernández-Rodríguez C; Bento L; Diez-Feijóo R; Pinzón S; Gibert J; Fernández-Ibarrondo L; Lafuente M; Ferrer A; Sánchez-González B; Gimeno E; Sainz J; Ramos R; García JF; Colomo L; Bellosillo B; Gutiérrez A; Salar A
Blood Adv; 2023 Apr; 7(8):1606-1614. PubMed ID: 36260737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]